Evidence map›Paper›PMID 35613581›Full record

ArticleCell reports2022

DDX41 is required for cGAS-STING activation against DNA virus infection.

Ravi Shankar Singh, Venkatasubramanian Vidhyasagar, Shizhuo Yang, Ananna Bhadra Arna, Manisha Yadav, Aanchal Aggarwal, Alexya N Aguilera, Satoru Shinriki, Kalpana Kalyanasundaram Bhanumathy, Kannupriya Pandey and 11 more

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
6.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Germline DDX41 mutations in myeloid neoplasms: a comprehensive review.The Korean journal of internal medicine · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. STING single amino acid polymorphisms modulate iridovirus immune evasion and pathogenicity spectrum.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 4 institutions in 3 countries.

Ravi Shankar SinghDepartment of Biochemistry, Microbiology and Immunology, University of Saskatchewan, Saskatoon SK S7N 5E5, Canada.
Venkatasubramanian VidhyasagarDepartment of Biochemistry, Microbiology and Immunology, University of Saskatchewan, Saskatoon SK S7N 5E5, Canada.
Shizhuo YangDepartment of Biochemistry, Microbiology and Immunology, University of Saskatchewan, Saskatoon SK S7N 5E5, Canada.
Ananna Bhadra ArnaDepartment of Biochemistry, Microbiology and Immunology, University of Saskatchewan, Saskatoon SK S7N 5E5, Canada.
Manisha YadavDepartment of Biochemistry, Microbiology and Immunology, University of Saskatchewan, Saskatoon SK S7N 5E5, Canada.
Aanchal AggarwalDepartment of Biochemistry, Microbiology and Immunology, University of Saskatchewan, Saskatoon SK S7N 5E5, Canada.
Alexya N AguileraDepartment of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
Satoru ShinrikiDepartment of Molecular Laboratory Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Kalpana Kalyanasundaram BhanumathySaskatchewan Cancer Agency, Saskatoon, SK S7N 5E5, Canada.
Kannupriya PandeyVaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac), University of Saskatchewan, Saskatoon, SK S7N 5E3, Canada.
Aizhang XuSaskatchewan Cancer Agency, Saskatoon, SK S7N 5E5, Canada.
Noreen RapinDepartment of Veterinary Microbiology, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, SK S7N 5B4, Canada.
Mark BoschSaskatchewan Cancer Agency, Saskatoon, SK S7N 5E5, Canada.
John DeCoteauDepartment of Pathology and Laboratory Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.
Jim XiangSaskatchewan Cancer Agency, Saskatoon, SK S7N 5E5, Canada.
Franco J VizeacoumarSaskatchewan Cancer Agency, Saskatoon, SK S7N 5E5, Canada; Department of Pathology and Laboratory Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.
Yan ZhouVaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac), University of Saskatchewan, Saskatoon, SK S7N 5E3, Canada; Department of Veterinary Microbiology, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, SK S7N 5B4, Canada.
Vikram MisraDepartment of Veterinary Microbiology, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, SK S7N 5B4, Canada.
Hirotaka MatsuiDepartment of Molecular Laboratory Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Susan R RossDepartment of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
Yuliang WuDepartment of Biochemistry, Microbiology and Immunology, University of Saskatchewan, Saskatoon SK S7N 5E5, Canada. Electronic address: yuliang.wu@usask.ca.
University of Saskatchewan · CASaskatchewan Cancer Agency · CAKumamoto University · JPUniversity of Illinois Chicago · US

Funding

Role of APOBEC3 in in vivo Restriction of Retrovirus InfectionR01AI085015 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ROSS, SUSAN R · 2010 to 2019
$3.9M
Role of APOBEC3 in in vivo Restriction of Retrovirus InfectionR56AI085015 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ROSS, SUSAN R · 2022 to 2022
$480k
Role of DDX41 in HSC development and MDS/AMLR21AI153594 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ROSS, SUSAN R · 2021 to 2022
$440k
NIAID NIH HHS R01 AI085015NIAID NIH HHS R21 AI153594NIAID NIH HHS R56 AI085015
6 · The paper itself

Abstract

Upon binding double-stranded DNA (dsDNA), cyclic GMP-AMP synthase (cGAS) is activated and initiates the cGAS-stimulator of IFN genes (STING)-type I interferon pathway. DEAD-box helicase 41 (DDX41) is a DEAD-box helicase, and mutations in DDX41 cause myelodysplastic syndromes (MDSs) and acute myeloid leukemia (AML). Here, we show that DDX41-knockout (KO) cells have reduced type I interferon production after DNA virus infection. Unexpectedly, activations of cGAS and STING are affected in DDX41 KO cells, suggesting that DDX41 functions upstream of cGAS. The recombinant DDX41 protein exhibits ATP-dependent DNA-unwinding activity and ATP-independent strand-annealing activity. The MDS/AML-derived mutant R525H has reduced unwinding activity but retains normal strand-annealing activity and stimulates greater cGAS dinucleotide-synthesis activity than wild-type DDX41. Overexpression of R525H in either DDX41-deficient or -proficient cells results in higher type I interferon production. Our results have led to the hypothesis that DDX41 utilizes its unwinding and annealing activities to regulate the homeostasis of dsDNA and single-stranded DNA (ssDNA), which, in turn, regulates cGAS-STING activation.

Indexed as

DNA Virus InfectionsInterferon Type ILeukemia, Myeloid, AcuteAdenosine TriphosphateDEAD-box RNA HelicasesDNAHumansMembrane ProteinsNucleotidyltransferasesSignal TransductionSTING ProteinAdenosine TriphosphateDDX41 protein, humanDEAD-box RNA HelicasesDNAInterferon Type IMembrane ProteinsNucleotidyltransferasesSTING1 protein, humanSTING Proteinacute myeloid leukemiaAMLannealingcGASCP: ImmunologyCP: Molecular biologyDDX41DNA virusMDSmyelodysplastic syndromesSTINGunwinding

Identifiers

PMID35613581
PMCPMC9205463
OpenAlexW4281398472

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.